What we do Suven Life Sciences is a clinical-stage biopharmaceutical company specializing in novel therapeutics for neurodegenerative disorders, along with contract research and manufacturing services. |
Founded in 1,989 |
Market share Leading CNS-focused drug discovery firm in India and Asia with unique GPCR-targeted therapies portfolio. |
Problem solved Addresses unmet medical needs in neurodegenerative and CNS disorders with innovative medicines and therapies. |
Top clients or who we serve Serves global life science companies through CRAMS and targets patients with CNS disorders; B2B and B2C focus. |
Key management Venkateswarlu Jasti, Chairman and Managing Director, leading since inception with visionary expertise. |
Our journey and innovations Evolved from specialty chemicals to biopharmaceuticals and CNS drug discovery; advanced multiple clinical-stage molecules. |
Where we operate Operations primarily in India, with clinical development in USA and markets including Europe and others. |
Top products or what we offer Contract manufacturing, custom synthesis, and novel CNS drug candidates like Masupirdine, Samelisant, and Ropanicant. |
Top brands SUVN-502 (Masupirdine) - Phase 3; SUVN-G3031 (Samelisant) - Phase 2/3; SUVN-911 (Ropanicant) - Phase 2; others in pipeline. |
Raw materials needed Pharmaceutical chemicals, active pharmaceutical ingredients, and specialized reagents for drug synthesis. |
Raw materials supplier Suppliers range from global life science chemical providers to specialty raw material vendors. |
Recurring vs cyclical contribution Majority revenue from contract research is recurring; clinical-stage drug development represents cyclical R&D investment. |
Our industry position Prominent in CNS drug discovery within India and Asia, with an expanding international clinical presence. |
Financial highlights 2024-25 revenue Rs. 666 Lakhs; net loss of Rs. 4,708 Lakhs standalone, reflecting R&D investments in drug candidates. |
Geographical revenue split Revenue mainly from India; smaller contributions from USA, Europe, and other regions. |
Order book Order book details not disclosed but services secure recurring CRAMS contracts. |
Whats driving growth Growth fueled by CNS drug pipeline progression, increased R&D, and expanding contract manufacturing business. |
Our future plans Advance lead clinical molecules through late-stage trials and expand manufacturing capabilities internationally. |
Our green promise Committed to sustainable practices and ethical business conduct, detailed ESG policies available on website. |
Our people and values Employee-centric culture focused on innovation, integrity, and global collaboration with diversity and inclusion. |
Key challenges ahead Managing high R&D costs, regulatory approvals, and competitive pressures in CNS drug development. |
Interesting facts One of the few Indian firms with multiple CNS molecules in advanced clinical stages globally. |
Risks and strategy Mitigates clinical and market risks via IP protection, diversified CRAMS revenue, and strategic partnerships. |
